Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Hansson, Markus  [Clear All Filters]
Journal Article
Nielsen LKongsgaard, Schjesvold F, Möller S, Guldbrandsen N, Hansson M, Remes K, Peceliunas V, Abildgaard N, Gregersen H, King MT. Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic . J Patient Rep Outcomes. 2024;8(1):15.
Lisak M, Nicklasson M, Palmason R, Wichert S, Isaksson C, Andersson P-O, Johansson J-E, Lenhoff S, Brune M, Hansson M. Higher cyclosporine-A concentration increases the risk of relapse in AML following allogeneic stem cell transplantation from unrelated donors using anti-thymocyte globulin. Sci Rep. 2023;13(1):22777.
Zweegman S, van der Holt B, Mellqvist U-H, Salomo M, Bos GMJ, Levin M-D, Visser-Wisselaar H, Hansson M, van der Velden AWG, Deenik W, et al. Lenalidomide plus melphalan and prednisone, followed by lenalidomide maintenance versus thalidomide plus melphalan and prednisone, followed by thalidomide maintenance; results of the randomised phase 3 HOVON 87/NMSG18 trial. Blood. 2016.
Wålinder G, Samuelsson J, Näsman P, Hansson M, Juliusson G, Forsberg K, Svensson R, Linder O, Carlson K, Kristinsson SY, et al. Outcome and characteristics of non-measurable myeloma: A cohort study with population-based data from the Swedish Myeloma Registry. Eur J Haematol. 2019.